HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock.

Abstract
Hemorrhagic shock (HS) and trauma is currently the leading cause of death in young adults worldwide. Morbidity and mortality after HS and trauma is often the result of multi-organ failure such as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), conditions with few therapeutic options. Bone marrow derived mesenchymal stem cells (MSCs) are a multipotent stem cell population that has shown therapeutic promise in numerous pre-clinical and clinical models of disease. In this paper, in vitro studies with pulmonary endothelial cells (PECs) reveal that conditioned media (CM) from MSCs and MSC-PEC co-cultures inhibits PEC permeability by preserving adherens junctions (VE-cadherin and β-catenin). Leukocyte adhesion and adhesion molecule expression (VCAM-1 and ICAM-1) are inhibited in PECs treated with CM from MSC-PEC co-cultures. Further support for the modulatory effects of MSCs on pulmonary endothelial function and inflammation is demonstrated in our in vivo studies on HS in the rat. In a rat "fixed volume" model of mild HS, we show that MSCs administered IV potently inhibit systemic levels of inflammatory cytokines and chemokines in the serum of treated animals. In vivo MSCs also inhibit pulmonary endothelial permeability and lung edema with concurrent preservation of the vascular endothelial barrier proteins: VE-cadherin, Claudin-1, and Occludin-1. Leukocyte infiltrates (CD68 and MPO positive cells) are also decreased in lungs with MSC treatment. Taken together, these data suggest that MSCs, acting directly and through soluble factors, are potent stabilizers of the vascular endothelium and inflammation. These data are the first to demonstrate the therapeutic potential of MSCs in HS and have implications for the potential use of MSCs as a cellular therapy in HS-induced lung injury.
AuthorsShibani Pati, Michael H Gerber, Tyler D Menge, Kathryn A Wataha, Yuhai Zhao, John Adam Baumgartner, Jing Zhao, Phillip A Letourneau, Maria P Huby, Lisa A Baer, John R Salsbury, Rosemary A Kozar, Charles E Wade, Peter A Walker, Pramod K Dash, Charles S Cox Jr, Marie-Francoise Doursout, John B Holcomb
JournalPloS one (PLoS One) Vol. 6 Issue 9 Pg. e25171 ( 2011) ISSN: 1932-6203 [Electronic] United States
PMID21980392 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD
  • Cadherins
  • Chemokine CCL3
  • Culture Media, Conditioned
  • Tumor Necrosis Factor-alpha
  • beta Catenin
  • cadherin 5
  • Intercellular Adhesion Molecule-1
  • Interleukin-10
Topics
  • Animals
  • Antigens, CD (metabolism)
  • Bone Marrow Cells (cytology, drug effects)
  • Cadherins (metabolism)
  • Cell Adhesion (physiology)
  • Cell Line
  • Cells, Cultured
  • Chemokine CCL3 (metabolism)
  • Culture Media, Conditioned (pharmacology)
  • Endothelial Cells (cytology)
  • Flow Cytometry
  • Humans
  • Immunohistochemistry
  • Intercellular Adhesion Molecule-1 (metabolism)
  • Interleukin-10 (metabolism)
  • Leukocytes (metabolism)
  • Lung (metabolism, pathology)
  • Male
  • Mesenchymal Stem Cells (cytology, physiology)
  • Rats
  • Rats, Sprague-Dawley
  • Shock, Hemorrhagic (metabolism, therapy)
  • Tumor Necrosis Factor-alpha (metabolism)
  • beta Catenin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: